HK1091499A1 - Methods for preventing and treating alzheimers disease (ad) (ad) - Google Patents

Methods for preventing and treating alzheimers disease (ad) (ad)

Info

Publication number
HK1091499A1
HK1091499A1 HK06111905.5A HK06111905A HK1091499A1 HK 1091499 A1 HK1091499 A1 HK 1091499A1 HK 06111905 A HK06111905 A HK 06111905A HK 1091499 A1 HK1091499 A1 HK 1091499A1
Authority
HK
Hong Kong
Prior art keywords
arg
glu
asp
tyr
phe
Prior art date
Application number
HK06111905.5A
Other languages
English (en)
Chinese (zh)
Inventor
Frank Mattner
Original Assignee
阿法爾斯研發有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 阿法爾斯研發有限責任公司 filed Critical 阿法爾斯研發有限責任公司
Publication of HK1091499A1 publication Critical patent/HK1091499A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
HK06111905.5A 2003-01-14 2006-10-27 Methods for preventing and treating alzheimers disease (ad) (ad) HK1091499A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT362003 2003-01-14
AT0146403A AT413945B (de) 2003-01-14 2003-09-17 Impfstoff für die alzheimer-krankheit
PCT/EP2004/000162 WO2004062556A2 (en) 2003-01-14 2004-01-13 Methods for preventing and treating alzheimer’s disease (ad)

Publications (1)

Publication Number Publication Date
HK1091499A1 true HK1091499A1 (en) 2007-01-19

Family

ID=32714004

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06111905.5A HK1091499A1 (en) 2003-01-14 2006-10-27 Methods for preventing and treating alzheimers disease (ad) (ad)

Country Status (15)

Country Link
US (2) US7732568B2 (xx)
EP (2) EP1679319B1 (xx)
JP (2) JP4547373B2 (xx)
CN (2) CN102526699A (xx)
AT (3) AT413945B (xx)
CA (1) CA2513218C (xx)
CY (2) CY1107146T1 (xx)
DE (2) DE602004009705T2 (xx)
DK (2) DK1679319T3 (xx)
ES (2) ES2296084T3 (xx)
HK (1) HK1091499A1 (xx)
PL (1) PL209989B1 (xx)
PT (2) PT1583774E (xx)
SI (1) SI1583774T1 (xx)
WO (1) WO2004062556A2 (xx)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056318A2 (en) 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AT413336B (de) * 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
US20070172496A1 (en) * 2004-01-28 2007-07-26 Curix Aps Conjugates of amyloid proteins as vaccines for amyloid-related diseases
AT413946B (de) * 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
AT500483B1 (de) 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
CN102898519B (zh) 2005-11-30 2015-10-28 Abbvie公司 抗淀粉样β蛋白的单克隆抗体及其用途
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
KR101505201B1 (ko) 2005-12-12 2015-03-24 에이씨 이뮨 에스.에이. 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
CL2007002070A1 (es) * 2006-07-14 2008-02-08 Ac Immune S A Genentech Inc Anticuerpo quimerico o humanizado, o fragmentos de ellos, que se adhieren especificamente a por lo menos un epitopo en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; su uso para tratar enfermedade
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
EP2574345A1 (en) * 2007-06-12 2013-04-03 AC Immune S.A. Humanized antibodies to amyloid beta
EP2650308A3 (en) * 2007-10-05 2014-11-12 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
BRPI0818621A8 (pt) * 2007-10-05 2018-01-30 Ac Immune Sa composição farmacêutica, e, métodos para reduzir a carga da placa e a quantidade de placas na camada de célula de gânglio retinal de um indivíduo, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular, para diagnosticar uma doença ocular e uma predisposição a uma doença ocular, para monitorar doença ocular, para predizer responsividade de um paciente, e para reter ou diminuir pressão ocular nos olhos de um indivíduo
WO2009048539A2 (en) * 2007-10-05 2009-04-16 Genentech, Inc. Monoclonal antibody
JP5219225B2 (ja) * 2007-10-25 2013-06-26 国立大学法人 鹿児島大学 アミロイドβペプチドのミミック分子を用いたペプチドワクチン
CN104098695B (zh) * 2007-10-29 2018-09-07 道健康生活医药株式会社 抗体及其应用
US8546532B2 (en) 2008-04-17 2013-10-01 Declion Pharmaceuticals, Inc. Synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
AT506820B1 (de) * 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
WO2009149487A2 (en) * 2008-06-12 2009-12-17 Affiris Ag Compounds for treating symptoms associated with parkinson's disease
AT506819B1 (de) * 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
NZ606357A (en) 2010-07-30 2015-05-29 Genentech Inc Safe and functional humanized anti beta-amyloid antibody
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
SI2579042T1 (sl) 2011-10-04 2014-09-30 Affiris Ag Postopek za detektiranje Ass-specifičnih protiteles v biološkem vzorcu
EP2787347A1 (en) 2013-04-03 2014-10-08 Affiris AG Method for detecting Aß-specific antibodies in a biological sample
US10381614B2 (en) * 2013-04-17 2019-08-13 Samsung Sdi Co., Ltd. Battery module
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
AU2016348610B2 (en) 2015-11-03 2023-08-31 Ac Immune Sa Method for vaccination against a self-antigen in a human patient
CN105237628B (zh) * 2015-11-17 2018-08-07 南开大学 一种用于治疗阿尔兹海默症的多肽
CN107022019B (zh) * 2016-11-24 2020-10-30 桂林医学院 一种用于脑内降铁除自由基的多肽、制备方法与应用
WO2023161526A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US5650489A (en) * 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
GB9022190D0 (en) * 1990-10-12 1990-11-28 Perham Richard N Immunogenic material
US5639603A (en) * 1991-09-18 1997-06-17 Affymax Technologies N.V. Synthesizing and screening molecular diversity
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6088993A (en) 1999-02-05 2000-07-18 Irace; Francisco D. Closure system
EP1156825A2 (en) 1999-02-25 2001-11-28 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogens comprising a peptide and a carrier derived from h.influenzae protein d
US6703491B1 (en) * 1999-03-17 2004-03-09 Exelixis, Inc. Drosophila sequences
IL142948A0 (en) * 1999-09-03 2002-04-21 Univ Ramot Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
DE60103137T2 (de) 2000-03-03 2005-05-25 Glaxosmithkline Biologicals S.A. Impstoff zur behandlung von atherosclerosis
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
DE50111493D1 (de) 2001-09-03 2007-01-04 Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh Antigen-Mimotope und Vakzine gegen Krebserkrankungen
ATE434186T1 (de) 2002-05-07 2009-07-15 Pasteur Institut Screeningverfahren für pp1-wechselwirkende polypeptide oder proteine, peptide, die die bindung von pp1c an die proteine bcl-2, bcl-xl und bcl-w hemmen, und ihre verwendung

Also Published As

Publication number Publication date
DE602004009705D1 (de) 2007-12-06
ES2339447T3 (es) 2010-05-20
WO2004062556A2 (en) 2004-07-29
PT1583774E (pt) 2010-04-07
DK1679319T3 (da) 2008-01-28
SI1583774T1 (sl) 2010-06-30
PT1679319E (pt) 2008-01-10
AU2004204349A1 (en) 2004-07-29
JP5282058B2 (ja) 2013-09-04
DE602004009705T2 (de) 2008-06-05
JP4547373B2 (ja) 2010-09-22
CY1107146T1 (el) 2012-05-23
ES2339447T8 (es) 2011-05-26
WO2004062556A3 (en) 2004-09-16
EP1583774A2 (en) 2005-10-12
WO2004062556A8 (en) 2004-10-21
CY1110634T1 (el) 2015-04-29
EP1679319A1 (en) 2006-07-12
CN1826354A (zh) 2006-08-30
US20060111301A1 (en) 2006-05-25
CA2513218C (en) 2013-06-25
ATE458753T1 (de) 2010-03-15
US7732568B2 (en) 2010-06-08
JP2006515876A (ja) 2006-06-08
JP2010174024A (ja) 2010-08-12
DE602004025668D1 (de) 2010-04-08
ATA14642003A (de) 2005-11-15
PL209989B1 (pl) 2011-11-30
EP1679319B1 (en) 2007-10-24
CN1826354B (zh) 2014-01-08
AT413945B (de) 2006-07-15
US20110015131A1 (en) 2011-01-20
ATE376559T1 (de) 2007-11-15
CA2513218A1 (en) 2004-07-29
PL378333A1 (pl) 2006-03-20
EP1583774B1 (en) 2010-02-24
ES2296084T3 (es) 2008-04-16
DK1583774T3 (da) 2010-05-03
CN102526699A (zh) 2012-07-04

Similar Documents

Publication Publication Date Title
HK1091499A1 (en) Methods for preventing and treating alzheimers disease (ad) (ad)
TW200602071A (en) Methods for preventing and treating alzheimer's disease (ad)
NO20045021L (no) Immunologiske metoder og preparater for behandling av Alzheimers sykdom
ATE283289T1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
AT500379B8 (de) Tau-proteine
BR0213565A (pt) Anticorpo de anti-tnf alfa modificado
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
AU2002302255A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
WO2004006952A3 (en) Therapeutic tuberculosis vaccines
WO2000073430A3 (de) Vakzine gegen konformationsabhängige antigene sowie gegen antigene, die keine oder nicht ausschliesslich proteine oder peptide sind
DE60313437D1 (de) Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4
EP2628750A3 (en) Targeted identification of immunogenic peptides
FR2804027B1 (fr) Utilisation d'anticorps monoclonaux anti-ferritines dans le traitement de certains cancers
WO1995020658A3 (en) Diagnosis and treatment of infections due to streptococci and enterococci
EE200000478A (et) Peptiid, seda kodeeriv geen, diagnostiline reagent ja diagnostiline reaktiivikomplekt ning vaktsiinkasutamiseks riketsioosi ravis
WO2004113386A3 (en) Modified hirudin proteins and t-cell epitopes in hirudin
HUP0303150A2 (hu) Csökkentett immunogenitású, módosított keratinocita növekedési faktor (KGF)
WO2007030771A3 (en) Targeted identification of immunogenic peptides
AU2001281943A1 (en) The t-cell protein (tzon7), peptides and antibodies derived therefrom and uses thereof
WO2004011496A3 (en) Novel t-cell proteins, peptides and antibodies derived therefrom and uses thereof
AU2002350406A1 (en) Identification of ses-3 (spr-5) in c. elegans and the uses of the same
WO2002008393A3 (en) Serine protease from yersinia enterocolitica
WO2002046380A3 (en) Protein kinase
WO2002062996A1 (fr) Nouveau peptide physiologiquement actif et utilisation de ce peptide

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180113